sorafenib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors 2459 284461-73-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BAY 43-9006
  • BAY 545-9085
  • BAY-545-9085
  • sorafenib tosilate
  • sorafenib
  • nexavar
  • sorafenib tosylate
Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-beta). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis were observed in models of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.
  • Molecular weight: 464.83
  • Formula: C21H16ClF3N4O3
  • CLOGP: 5.46
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 3
  • TPSA: 92.35
  • ALOGS: -5.43
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.80 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 12.29 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 39 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 2005 FDA BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 1541.29 18.66 458 14330 21148 53313130
Hepatocellular carcinoma 1093.51 18.66 236 14552 2844 53331434
Hepatic cancer 274.14 18.66 80 14708 3421 53330857
Hepatic function abnormal 198.57 18.66 125 14663 36774 53297504
Diarrhoea 190.60 18.66 485 14303 625061 52709217
Hepatic encephalopathy 169.35 18.66 75 14713 10784 53323494
Decreased appetite 159.29 18.66 243 14545 214731 53119547
Renal cell carcinoma 158.93 18.66 53 14735 3526 53330752
Rash 143.76 18.66 354 14434 445837 52888441
Off label use 142.09 18.66 365 14423 471847 52862431
Blister 135.07 18.66 136 14652 78617 53255661
Hypertension 121.51 18.66 221 14567 225210 53109068
Metastases to lung 121.33 18.66 61 14727 11643 53322635
Hyperkeratosis 109.98 18.66 45 14743 5321 53328957
Thyroid cancer 108.01 18.66 42 14746 4348 53329930
Skin exfoliation 98.60 18.66 81 14707 36002 53298276
Drug ineffective 91.87 18.66 57 14731 817188 52517090
Ascites 91.80 18.66 81 14707 39654 53294624
Alopecia 83.65 18.66 194 14594 234389 53099889
Amylase increased 82.64 18.66 38 14750 5956 53328322
Dry skin 80.17 18.66 80 14708 45680 53288598
Stomatitis 76.79 18.66 114 14674 98044 53236234
Pain of skin 75.45 18.66 40 14748 8512 53325766
Product use in unapproved indication 74.69 18.66 121 14667 112168 53222110
Rheumatoid arthritis 74.32 18.66 3 14785 314528 53019750
Alpha 1 foetoprotein increased 69.76 18.66 15 14773 176 53334102
Lipase increased 63.90 18.66 37 14751 9341 53324937
Metastatic renal cell carcinoma 62.10 18.66 19 14769 955 53333323
Hepatic failure 56.17 18.66 59 14729 35747 53298531
Erythema multiforme 55.46 18.66 35 14753 10314 53323964
Palmoplantar keratoderma 52.94 18.66 11 14777 108 53334170
Drug hypersensitivity 52.64 18.66 6 14782 265236 53069042
Erythema 50.65 18.66 125 14663 156844 53177434
Ammonia increased 44.95 18.66 23 14765 4550 53329728
Skin toxicity 41.43 18.66 21 14767 4072 53330206
Blood bilirubin increased 40.91 18.66 50 14738 35680 53298598
Platelet count decreased 39.07 18.66 90 14698 108009 53226269
Food refusal 37.28 18.66 10 14778 312 53333966
Hypophosphataemia 35.62 18.66 25 14763 8780 53325498
Catabolic state 34.76 18.66 7 14781 58 53334220
Thyroid cancer metastatic 34.17 18.66 8 14780 141 53334137
Protein induced by vitamin K absence or antagonist II increased 33.61 18.66 5 14783 3 53334275
Blood pressure increased 33.38 18.66 100 14688 140379 53193899
Pain in extremity 32.84 18.66 161 14627 284889 53049389
Condition aggravated 32.79 18.66 21 14767 297113 53037165
Liver carcinoma ruptured 32.02 18.66 5 14783 6 53334272
Liver disorder 30.44 18.66 46 14742 40109 53294169
Weight decreased 30.18 18.66 137 14651 234811 53099467
Pancreatic enzymes increased 29.30 18.66 10 14778 713 53333565
Hospitalisation 28.88 18.66 62 14726 70950 53263328
Arthropathy 28.54 18.66 3 14785 141450 53192828
Abdominal pain 28.37 18.66 143 14645 255760 53078518
Tumour necrosis 28.36 18.66 10 14778 786 53333492
Oral pain 28.23 18.66 36 14752 26801 53307477
Weight increased 27.74 18.66 11 14777 204556 53129722
Hyperammonaemia 26.55 18.66 17 14771 5132 53329146
Sinusitis 26.49 18.66 7 14781 168557 53165721
Death 25.03 18.66 177 14611 357055 52977223
Acute myeloid leukaemia 24.95 18.66 27 14761 16905 53317373
Plantar erythema 24.79 18.66 7 14781 265 53334013
Mucosal inflammation 24.28 18.66 43 14745 42741 53291537
Swelling 23.21 18.66 12 14776 191093 53143185
Tumour thrombosis 22.98 18.66 4 14784 13 53334265
Joint swelling 22.73 18.66 19 14769 234619 53099659
Gait inability 22.38 18.66 39 14749 38272 53296006
Pain 22.26 18.66 86 14702 588312 52745966
Pyrexia 22.26 18.66 189 14599 403004 52931274
Acute myeloid leukaemia recurrent 22.14 18.66 10 14778 1503 53332775
Soft tissue necrosis 21.65 18.66 7 14781 422 53333856
Bronchitis 21.04 18.66 3 14785 111896 53222382
Malignant neoplasm progression 20.98 18.66 55 14733 71486 53262792
Nasopharyngitis 20.64 18.66 14 14774 192281 53141997
Jaundice 20.57 18.66 33 14755 30280 53303998
Metastases to bone 20.44 18.66 26 14762 19302 53314976
Asthma 20.30 18.66 3 14785 108969 53225309
Hypocalcaemia 19.99 18.66 32 14756 29305 53304973
Hepatic rupture 19.88 18.66 4 14784 33 53334245
Dysphonia 19.86 18.66 39 14749 41899 53292379
Disease progression 19.16 18.66 67 14721 101853 53232425
Tumour haemorrhage 19.01 18.66 9 14779 1505 53332773
Asthenia 18.91 18.66 161 14627 343429 52990849
Coma hepatic 18.71 18.66 7 14781 652 53333626
Osteosarcoma 18.67 18.66 5 14783 155 53334123

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular carcinoma 3903.23 16.25 1090 35173 9180 32468083
Palmar-plantar erythrodysaesthesia syndrome 3690.07 16.25 1149 35114 14600 32462663
Hepatic cancer 1047.38 16.25 368 35895 6872 32470391
Hepatic function abnormal 619.77 16.25 463 35800 44377 32432886
Hepatic encephalopathy 556.96 16.25 290 35973 14605 32462658
Diarrhoea 550.50 16.25 1233 35030 363569 32113694
Ascites 480.74 16.25 381 35882 39810 32437453
Renal cell carcinoma 440.46 16.25 186 36077 5784 32471479
Decreased appetite 422.63 16.25 690 35573 160123 32317140
Hypertension 378.42 16.25 589 35674 131161 32346102
Metastases to lung 337.95 16.25 172 36091 8245 32469018
Alopecia 324.41 16.25 231 36032 20499 32456764
Hepatic failure 314.75 16.25 284 35979 35396 32441867
Blister 258.68 16.25 207 36056 21884 32455379
Dysphonia 248.99 16.25 197 36066 20487 32456776
Alpha 1 foetoprotein increased 224.60 16.25 66 36197 668 32476595
Rash 183.84 16.25 581 35682 208752 32268511
Amylase increased 160.39 16.25 94 36169 5961 32471302
Liver carcinoma ruptured 143.85 16.25 34 36229 130 32477133
Metastatic renal cell carcinoma 135.09 16.25 63 36200 2486 32474777
Drug ineffective 132.50 16.25 140 36123 383337 32093926
Ammonia increased 130.76 16.25 74 36189 4390 32472873
Blood bilirubin increased 117.31 16.25 178 36085 38606 32438657
Hyperkeratosis 110.49 16.25 61 36202 3448 32473815
Stomatitis 108.29 16.25 175 36088 40054 32437209
Skin exfoliation 103.73 16.25 134 36129 25023 32452240
Toxicity to various agents 101.46 16.25 36 36227 178005 32299258
Jaundice 100.80 16.25 155 36108 34003 32443260
Lipase increased 98.32 16.25 82 36181 9175 32468088
Liver disorder 98.16 16.25 147 36116 31507 32445756
Oesophageal varices haemorrhage 96.64 16.25 54 36209 3125 32474138
Drug interaction 95.66 16.25 63 36200 218122 32259141
Acute kidney injury 94.77 16.25 113 36150 293355 32183908
Metastases to bone 91.86 16.25 84 36179 10626 32466637
Dry skin 83.22 16.25 120 36143 24858 32452405
Completed suicide 83.18 16.25 5 36258 92512 32384751
Fatigue 81.74 16.25 668 35595 350033 32127230
Overdose 77.40 16.25 5 36258 87072 32390191
Tumour rupture 76.97 16.25 22 36241 200 32477063
Hypophosphataemia 76.88 16.25 70 36193 8805 32468458
Metastases to lymph nodes 75.39 16.25 52 36211 4376 32472887
Portal vein thrombosis 68.67 16.25 46 36217 3689 32473574
Pain of skin 64.69 16.25 46 36217 4064 32473199
Platelet count decreased 64.60 16.25 276 35987 114315 32362948
Blood pressure increased 61.90 16.25 212 36051 79142 32398121
Abdominal pain 61.67 16.25 329 35934 149200 32328063
Abdominal pain upper 60.71 16.25 189 36074 67149 32410114
Tumour thrombosis 57.77 16.25 14 36249 61 32477202
Fall 56.60 16.25 82 36181 196119 32281144
Pneumonia 55.98 16.25 206 36057 355046 32122217
Hypotension 55.12 16.25 98 36165 216012 32261251
Hepatorenal syndrome 54.54 16.25 35 36228 2610 32474653
Erythema multiforme 53.85 16.25 58 36205 8934 32468329
Aspartate aminotransferase increased 53.14 16.25 179 36084 66250 32411013
Weight decreased 52.63 16.25 339 35924 164479 32312784
Metastases to adrenals 50.23 16.25 24 36239 1000 32476263
Protein induced by vitamin K absence or antagonist II increased 49.68 16.25 10 36253 13 32477250
Pain in extremity 49.24 16.25 262 36001 118639 32358624
Off label use 48.94 16.25 539 35724 305781 32171482
Drug hypersensitivity 48.86 16.25 11 36252 73389 32403874
Metastases to central nervous system 48.42 16.25 51 36212 7657 32469606
Metastases to spine 47.70 16.25 31 36232 2362 32474901
Asthenia 46.69 16.25 434 35829 235510 32241753
Pancreatic enzymes increased 46.64 16.25 20 36243 645 32476618
Skin fissures 46.55 16.25 37 36226 3866 32473397
Neutropenia 45.48 16.25 55 36208 142120 32335143
Coma hepatic 45.45 16.25 18 36245 472 32476791
Skin toxicity 45.22 16.25 36 36227 3770 32473493
Gait inability 43.12 16.25 79 36184 19968 32457295
Hepatic rupture 40.26 16.25 9 36254 25 32477238
Renal cell carcinoma stage IV 40.14 16.25 10 36253 50 32477213
Cardiac arrest 39.61 16.25 30 36233 96746 32380517
Tumour marker increased 39.56 16.25 17 36246 551 32476712
Metastases to peritoneum 39.27 16.25 24 36239 1642 32475621
Liver abscess 38.05 16.25 32 36231 3619 32473644
Malignant neoplasm progression 37.41 16.25 180 36083 78316 32398947
Weight increased 36.79 16.25 24 36239 83639 32393624
Condition aggravated 36.65 16.25 74 36189 155587 32321676
Depression 34.95 16.25 34 36229 97026 32380237
Foetal exposure during pregnancy 34.90 16.25 3 36260 41298 32435965
Reactive perforating collagenosis 34.80 16.25 6 36257 0 32477263
Coronary artery disease 33.99 16.25 7 36256 49699 32427564
Cerebral infarction 33.15 16.25 86 36177 27528 32449735
Aggression 32.90 16.25 3 36260 39386 32437877
Tumour haemorrhage 32.64 16.25 26 36237 2725 32474538
Hospitalisation 32.35 16.25 124 36139 48847 32428416
Thyroid cancer 32.32 16.25 20 36243 1399 32475864
Product administered to patient of inappropriate age 32.18 16.25 26 36237 2780 32474483
Anxiety 31.91 16.25 36 36227 95969 32381294
Thyroid cancer metastatic 31.63 16.25 8 36255 43 32477220
Bradycardia 30.82 16.25 21 36242 71541 32405722
Agitation 30.18 16.25 13 36250 57223 32420040
Nephrotic syndrome 30.13 16.25 39 36224 7290 32469973
Therapeutic product effect incomplete 30.02 16.25 5 36258 41336 32435927
Varicose vein ruptured 29.99 16.25 7 36256 25 32477238
Gastric ulcer 28.72 16.25 58 36205 15751 32461512
Febrile neutropenia 27.14 16.25 58 36205 119508 32357755
Keratoacanthoma 27.07 16.25 13 36250 548 32476715
Lactic acidosis 26.85 16.25 3 36260 33533 32443730
Suicidal ideation 26.80 16.25 5 36258 38078 32439185
Haemobilia 26.77 16.25 11 36252 318 32476945
Influenza 26.68 16.25 9 36254 46005 32431258
Asthma 26.65 16.25 8 36255 44057 32433206
Inappropriate schedule of product administration 26.50 16.25 9 36254 45816 32431447
Hyperammonaemia 26.49 16.25 33 36230 5936 32471327
Cancer pain 26.44 16.25 23 36240 2723 32474540
Metastasis 26.25 16.25 26 36237 3631 32473632
Hyperamylasaemia 25.97 16.25 13 36250 600 32476663
Chronic obstructive pulmonary disease 25.82 16.25 11 36252 48742 32428521
Hepatic cancer metastatic 25.82 16.25 14 36249 763 32476500
Malaise 25.61 16.25 306 35957 176832 32300431
COVID-19 25.29 16.25 3 36260 32012 32445251
Oxygen saturation decreased 25.24 16.25 11 36252 48088 32429175
Genital rash 25.12 16.25 12 36251 500 32476763
Plantar erythema 25.06 16.25 7 36256 58 32477205
Tachycardia 24.84 16.25 31 36232 79057 32398206
Papillary thyroid cancer 24.83 16.25 13 36250 660 32476603
Intentional product misuse 24.80 16.25 5 36258 36046 32441217
Hepatic lesion 24.40 16.25 24 36239 3323 32473940
Electrocardiogram QT prolonged 24.33 16.25 7 36256 39634 32437629
Therapeutic product effect decreased 24.27 16.25 3 36260 31014 32446249
Incorrect dose administered 23.80 16.25 5 36258 35023 32442240
General physical health deterioration 23.72 16.25 214 36049 115045 32362218
Epistaxis 23.71 16.25 124 36139 55731 32421532
Rhabdomyolysis 23.71 16.25 24 36239 67241 32410022
Erythema 23.50 16.25 166 36097 82939 32394324
Hypersensitivity 23.50 16.25 18 36245 57740 32419523
Drug reaction with eosinophilia and systemic symptoms 23.43 16.25 4 36259 32481 32444782
Glossodynia 23.41 16.25 24 36239 3492 32473771
Nasopharyngitis 23.36 16.25 22 36241 63765 32413498
Sinusitis 23.30 16.25 6 36257 36554 32440709
Gastric antral vascular ectasia 23.25 16.25 10 36253 325 32476938
Pyrexia 23.11 16.25 492 35771 319476 32157787
Syncope 22.80 16.25 41 36222 90083 32387180
C-reactive protein increased 22.68 16.25 110 36153 47992 32429271
Abdominal distension 22.55 16.25 115 36148 51180 32426083
Cardiac failure congestive 22.01 16.25 38 36225 84814 32392449
Psoriasis 22.00 16.25 12 36251 46111 32431152
Wheezing 21.75 16.25 7 36256 36867 32440396
Haematemesis 21.66 16.25 74 36189 27561 32449702
Neuropathy peripheral 21.34 16.25 33 36230 76949 32400314
Hyperhidrosis 21.21 16.25 29 36234 71139 32406124
Chronic kidney disease 21.20 16.25 9 36254 39966 32437297
Alanine aminotransferase increased 21.17 16.25 155 36108 78324 32398939
Gingival bleeding 21.02 16.25 32 36231 6949 32470314
Cardio-respiratory arrest 20.86 16.25 19 36244 55970 32421293
Varices oesophageal 20.85 16.25 23 36240 3638 32473625
Hepatic infarction 20.78 16.25 8 36255 194 32477069
Proteinuria 20.78 16.25 54 36209 17301 32459962
Acute myeloid leukaemia recurrent 20.29 16.25 17 36246 1913 32475350
Lower respiratory tract infection 20.23 16.25 4 36259 29239 32448024
Intentional product use issue 20.10 16.25 11 36252 42200 32435063
Wrong technique in product usage process 20.07 16.25 7 36256 35052 32442211
Renal cancer metastatic 20.00 16.25 11 36252 617 32476646
Palmoplantar keratoderma 19.96 16.25 9 36254 328 32476935
Sepsis 19.48 16.25 101 36162 158733 32318530
Skin ulcer 19.36 16.25 59 36204 20700 32456563
Death 19.21 16.25 560 35703 381957 32095306
Product dose omission issue 19.17 16.25 55 36208 102520 32374743
Dizziness 19.16 16.25 146 36117 209472 32267791
Melaena 19.10 16.25 83 36180 34582 32442681
Urticaria 19.10 16.25 23 36240 59591 32417672
Metastases to pleura 18.75 16.25 9 36254 379 32476884
Septic shock 18.72 16.25 30 36233 68959 32408304
Hepatic artery thrombosis 18.37 16.25 8 36255 268 32476995
Follicular thyroid cancer 18.20 16.25 4 36259 10 32477253
Aortic dissection 17.82 16.25 18 36245 2572 32474691
Joint swelling 17.62 16.25 19 36244 51716 32425547
Glossitis 17.59 16.25 13 36250 1219 32476044
Faeces discoloured 17.51 16.25 46 36217 14831 32462432
Metastases to gallbladder 17.40 16.25 3 36260 0 32477263
Thyroid atrophy 17.40 16.25 3 36260 0 32477263
Poorly differentiated thyroid carcinoma 17.40 16.25 3 36260 0 32477263
Oropharyngeal blistering 17.35 16.25 7 36256 193 32477070
Hallucination 17.18 16.25 20 36243 52599 32424664
Feeding disorder 16.95 16.25 28 36235 6517 32470746
Food refusal 16.86 16.25 7 36256 208 32477055
Tumour embolism 16.80 16.25 5 36258 53 32477210
Cytomegalovirus infection 16.57 16.25 4 36259 25460 32451803
Hypoalbuminaemia 16.49 16.25 39 36224 11783 32465480
Leukopenia 16.45 16.25 26 36237 60096 32417167
Somnolence 16.38 16.25 60 36203 103737 32373526
Tremor 16.37 16.25 42 36221 81235 32396028

Pharmacologic Action:

SourceCodeDescription
ATC L01EX02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:38637 protein tyrosine kinase inhibitor
CHEBI has role CHEBI:48422 angiostatic agents
CHEBI has role CHEBI:50925 serine/threonine protein kinase inhibitors
CHEBI has role CHEBI:149553 anti-coronaviral agents
CHEBI has role CHEBI:173085 ferroptosis inducers

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Liver cell carcinoma indication 109841003 DOID:684
Carcinoma of thyroid indication 448216007
Renal cell carcinoma indication 702391001 DOID:4450
Hypophosphatemia contraindication 4996001
Acute hemorrhage contraindication 8573003
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Pancreatitis contraindication 75694006 DOID:4989
Angina pectoris contraindication 194828000
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Surgical procedure contraindication 387713003
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.84 acidic
pKa2 11.97 acidic
pKa3 12.61 acidic
pKa4 2.76 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8618141 Feb. 11, 2023 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8877933 Dec. 24, 2027 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.43 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase INHIBITOR Ki 8.22 CHEMBL CHEMBL
Serine/threonine-protein kinase B-raf Kinase INHIBITOR Ki 7.66 CHEMBL CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase INHIBITOR Kd 8.35 CHEMBL CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR Kd 8.13 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR Kd 7.51 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Ki 10.68 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 6.89 CHEMBL
Epidermal growth factor receptor Kinase IC50 8.53 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.09 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 6.41 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 5.57 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.08 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 5.70 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.55 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.21 CHEMBL
Cyclin-dependent kinase 2 Kinase Kd 5.06 CHEMBL
Insulin receptor Kinase AGONIST IC50 5.28 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.38 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.44 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.89 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 5.54 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.68 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 6.02 CHEMBL
Hepatocyte growth factor receptor Kinase IC50 5.24 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 5.52 CHEMBL
LIM domain kinase 1 Kinase Kd 5.80 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 5.60 CHEMBL
Cyclin-dependent-like kinase 5 Kinase Kd 5.21 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 5.47 CHEMBL
Aurora kinase C Kinase Kd 6.68 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 5.46 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 6.70 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 6.44 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 5.89 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.57 CHEMBL
Mitogen-activated protein kinase 3 Kinase IC50 7.74 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.62 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.10 CHEMBL
Mitogen-activated protein kinase 12 Kinase Kd 5.12 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.11 CHEMBL
Aurora kinase A Kinase IC50 5.42 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 5.42 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.59 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.36 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.12 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.80 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 5.77 CHEMBL
Ephrin type-A receptor 7 Kinase Kd 6.17 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.44 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 8.82 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.74 CHEMBL
Cyclin-dependent kinase 15 Kinase Kd 5.54 CHEMBL
Bifunctional epoxide hydrolase 2 Enzyme IC50 7.92 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.16 CHEMBL
Mitogen-activated protein kinase 1 Kinase IC50 6.96 CHEMBL
Cyclin-dependent kinase 6 Kinase IC50 6.89 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 5.35 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 5.68 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 5.72 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.85 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.12 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase 13 Kinase Kd 5.18 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.80 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 5.54 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 8.20 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 7.17 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.22 CHEMBL
LIM domain kinase 2 Kinase Kd 5.02 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 6.64 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 6.19 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.55 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.18 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 5.32 CHEMBL
Aurora kinase B Kinase Kd 6.36 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.32 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 5.44 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 6.60 CHEMBL
Cyclin-dependent kinase 8 Kinase Kd 6.51 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.89 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.21 CHEMBL
Myosin-IIIb Kinase Kd 5.15 CHEMBL
Cyclin-dependent kinase 3 Kinase Kd 5.42 CHEMBL
Tyrosine-protein kinase Srms Kinase Kd 5.01 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.51 CHEMBL
Mitogen-activated protein kinase 15 Kinase Kd 7.34 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase IC50 5.82 CHEMBL
Casein kinase I isoform alpha Kinase IC50 6.60 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 6.89 CHEMBL
Cyclin-dependent kinase-like 3 Kinase Kd 6.31 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.62 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 5.77 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 6.41 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 8.57 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 6.16 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.27 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.57 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.96 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.42 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 6.27 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.72 CHEMBL
Myosin light chain kinase 3 Kinase Kd 5.02 CHEMBL
Serine/threonine-protein kinase A-Raf Kinase IC50 8.15 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase IC50 4.84 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.07 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.14 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.93 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.71 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 7.25 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.38 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 5.21 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 5.15 CHEMBL
5-hydroxytryptamine receptor 5A GPCR Ki 5.48 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 6.65 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.66 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 7.82 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 5.59 CHEMBL
Purine nucleoside phosphorylase Enzyme IC50 7.90 CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR IC50 7.70 IUPHAR
Platelet-derived growth factor receptor beta Kinase INHIBITOR IC50 7.24 IUPHAR
Serine/threonine-protein kinase B-raf Kinase IC50 6.89 CHEMBL

External reference:

IDSource
4025077 VUID
N0000175349 NUI
D06272 KEGG_DRUG
475207-59-1 SECONDARY_CAS_RN
4025077 VANDF
C1516119 UMLSCUI
CHEBI:50924 CHEBI
BAX PDB_CHEM_ID
CHEMBL1336 ChEMBL_ID
CHEMBL1200485 ChEMBL_ID
D000077157 MESH_DESCRIPTOR_UI
DB00398 DRUGBANK_ID
5711 IUPHAR_LIGAND_ID
8234 INN_ID
9ZOQ3TZI87 UNII
216239 PUBCHEM_CID
495881 RXNORM
20792 MMSL
73580 MMSL
d05691 MMSL
011160 NDDF
011161 NDDF
420681006 SNOMEDCT_US
422042001 SNOMEDCT_US
432886002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nexavar HUMAN PRESCRIPTION DRUG LABEL 1 50419-488 TABLET, FILM COATED 200 mg ORAL NDA 28 sections